Hemogenyx Pharmaceuticals PLC Cash Flow-to-Debt Ratio
Hemogenyx Pharmaceuticals PLC cash flow-to-debt ratio. Hemogenyx Pharmaceuticals PLC (HEMO) has a Cash Flow-to-Debt Ratio of -0.53x as of December 2024, meaning its operating cash flow of GBX-1.78 Million could theoretically repay -1% of its total liabilities (GBX3.36 Million) in one year. Check earnings quality score of Hemogenyx Pharmaceuticals PLC to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hemogenyx Pharmaceuticals PLC (2015–2024)
Cash flow-to-debt ratio of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. Historical debt coverage capacity for Hemogenyx Pharmaceuticals PLC across 10 annual periods. Check Hemogenyx Pharmaceuticals PLC (HEMO) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Hemogenyx Pharmaceuticals PLC Cash Flow-to-Debt Ratio by Year (2015–2024)
Hemogenyx Pharmaceuticals PLC cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Hemogenyx Pharmaceuticals PLC. For the full cash flow conversion analysis, see HEMO cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.23x | GBX-4.12 Million | GBX3.36 Million | ▲ +33.2% |
| 2023 | -1.84x | GBX-6.11 Million | GBX3.32 Million | ▼ -142.8% |
| 2022 | -0.76x | GBX-2.91 Million | GBX3.85 Million | ▲ +89.8% |
| 2021 | -7.45x | GBX-2.63 Million | GBX352.84K | ▼ -640.7% |
| 2020 | -1.01x | GBX-1.80 Million | GBX1.79 Million | ▼ -17.2% |
| 2019 | -0.86x | GBX-1.20 Million | GBX1.40 Million | ▲ +15.0% |
| 2018 | -1.01x | GBX-1.35 Million | GBX1.34 Million | ▲ +41.3% |
| 2017 | -1.72x | GBX-452.98K | GBX263.69K | ▲ +11.3% |
| 2016 | -1.94x | GBX-278.15K | GBX143.69K | ▼ -599506.7% |
| 2015 | 0.00x | GBX79.71 | GBX246.83K | — |